CD70 signaling is critical for CD28-independent CD8+ T cell-mediated alloimmune responses in vivo

Journal of Immunology

Volumn 174, Issue 3, 2005, Pages 1357-1364

  Yamada, Akira ^a,b   Salama, Alan D ^a,e   Sho, Masayuki ^a   Najafian, Nader ^a   Ito, Toshiro ^a,b   Forman, John P ^a   Kewalramani, Reshma ^a   Sandner, Sigrid ^a   Harada, Hiroshi ^a   Clarkson, Michael R ^a   Mandelbrot, Didier A ^a   Sharpe, Arlene H ^a   Oshima, Hideo ^c   Yagita, Hideo ^a   Chalasani, Geetha ^d   Lakkis, Fadi G ^d   Auchincloss Jr , Hugh ^a,b   Sayegh, Mohamed H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c JUNTENDO UNIVERSITY   (Japan)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD27 ANTIGEN; CD28 ANTIGEN; CD70 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;

ALLOGRAFT; ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CELL ACTIVATION; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; EFFECTOR CELL; GRAFT SURVIVAL; IMMUNE RESPONSE; IN VIVO STUDY; MEMORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECIPIENT; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TH1 CELL; TRANSPLANTATION TOLERANCE; WILD TYPE;

EID: 19944430410     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.174.3.1357     Document Type: Article

References (64)

1. Sayegh, M. H., and L. A. Turka. 1998. The role of T-cell costimulatory activation pathways in transplant rejection. N. Engl. J. Med. 338:1813.
2. Salamon, B., and J. A. Bluestone. 2001. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu. Rev. Immunol. 19:225.
3. Sharpe, A. H., and G. J. Freeman. 2002. The B7-CD28 superfamily. Nat. Rev. Immunol. 2:116.
4. + T cells play a critical role in costimulation blockade-resistant allograft rejection. J. Clin. Invest. 104:1715.
5. Kirk, A. D., L. C. Burkly, D. S. Batty, R. E. Baumgartner, J. D. Berning, K. Buchanan, J. H. Fechner, Jr., R. L. Germond, R. L. Kampen, N. B. Patterson, et al. 1999. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat. Med. 5:686.
6. Kenyon, N. S., L. A. Fernandez, R. Lehmann, M. Masetti, A. Ranuncoli, M. Chatzipetrou, G. Iaria, D. Han, J. L. Wagner, P. Ruiz, et al. 1999. Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154. Diabetes 48:1473.
7. Kenyon, N. S., M. Chatzipetrou, M. Masetti, A. Ranuncoli, M. Oliveira, J. L. Wagner, A. D. Kirk, D. M. Harlan, L. C. Burkly, and C. Ricordi. 1999. Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Proc. Natl. Acad. Sci. USA 96:8132.
8. + T cells can trigger allograft rejection. J. Immunol. 165:1111.
9. Guo, Z., L. Meng, O. Kim, J. Wang, J. Hart, G. He, M. L. Alegre, J. R. Thistlethwaite, Jr., T. C. Pearson, C. P. Larsen, and K. A. Newell. 2001. CD8 T cell-mediated rejection of intestinal allografts is resistant to inhibition of the CD40/CD154 costimulatory pathway. Transplantation 71:1351.
10. Makhlouf, L., K. Kishimoto, R. N. Smith, R. Abdi, M. Koulmanda, H. J. Winn, H. J. Auchincloss, and M. H. Sayegh. 2002. The role of autoimmunity in islet allograft destruction: major histocompatibility complex class II matching is necessary for autoimmune destruction of allogeneic islet transplants after T-cell co-stimulatory blockade. Diabetes 51:3202.
11. Larsen, C. P., E. T. Elwood, D. Z. Alexander, S. C. Ritchie, R. Hendrix, C. Tucker-Burden, H. R. Cho, A. Aruffo, D. Hollenbaugh, P. S. Linsley, et al. 1996. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381:434.
12. Glysing-Jensen, T., A. Raisanen-Sokolowski, M. H. Sayegh, and M. E. Russell. 1997. Chronic blockade of CD28-B7-mediated T-cell costimulation by CTLA4Ig reduces intimal thickening in MHC class I and II incompatible mouse heart allografts. Transplantation 64:1641.
13. Sayegh, M. H., X. G. Zheng, C. Magee, W. W. Hancock, and L. A. Turka. 1997. Donor antigen is necessary for the prevention of chronic rejection in CTLA4Ig-treated murine cardiac allograft recipients. Transplantation 64:1646.
14. + T cells contribute to the development of transplant arteriosclerosis despite CD154 blockade. Transplantation 69:2609.
15. Salama, A. D., G. Remuzzi, W. E. Harmon, and M. H. Sayegh. 2001. Challenges to achieving clinical transplantation tolerance. J. Clin. Invest. 108:943.
16. Yamada, A., A. D. Salama, and M. H. Sayegh. 2002. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J. Am. Soc. Nephrol. 13:559.
17. Le Moine, A., and M. Goldman. 2003. Non-classical pathways of cell-mediated allograft rejection: new challenges for tolerance induction? Am. J. Transplant. 3:101.
18. + T cells. J. Immunol. 163:2358.
19. + T cells, interferon-γ. and CTLA4. J. Clin. Invest. 101:2446.
20. Mapara, M. Y., M. Pelot, G. Zhao, K. Swenson, D. Pearson, and M. Sykes. 2001. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance. Biol. Blood Marrow Transplant. 7:646.
21. Watts, T. H., and M. A. DeBenedelte. 1999. T cell co-stimulatory molecules other than CD28. Curr. Opin. Immunol 11:286.
22. Salama, A. D., and M. H. Sayegh. 2003. Alternative T-cell costimulatory pathways in transplant rejection and tolerance induction: hierarchy or redundancy? Am. J. Transplant. 3:509.
23. Rothstein, D. M., and M. H. Sayegh. 2003. T-cell costimulatory pathways in allograft rejection and tolerance. Immunol. Rev. 196:85.
24. + T cell proliferation and lead to the amplification in vivo of cytotoxic T cell response. J. Exp. Med. 186:47.
25. Yuan, X., A. D. Salama, V. Dong, I. Schmitt, N. Najafian, A. Chandraker, H. Akiba, H. Yagita, and M. H. Sayegh. 2003. The role of the CD134-CD134 ligand costimulatory pathway in alloimmune responses in vivo. J. Immunol. 170:2949.
26. + T cells. Am. J. Transplant. 3:543.
27. Harada, H., A. D. Salama, M. Sho, A. Izawa, S. E. Sandner, T. Ito, H. Akiba, H. Yagita, A. Sharpe, G. Freeman, and M. H. Sayegh. 2003. The role of the ICOS-B7h T cell costimulatory pathway intransplantation immunity. J. Clin. Invest. 112:234.
28. Ozkaynak, E., W. Gao, N. Shemmeri, C. Wang, J. C. Gutierrez-Ramos, J. Amaral, S. Qin, J. B. Rottman, A. J. Coyle, and W. W. Hancock. 2001. Importance of ICOS-B7RP-1 costimulation in acute and chronic allograft rejection. Nat. Immunol. 2:591.
29. Backstrom, B. T., U. Muller, B. Hausmann, and E. Palmer. 1998. Positive selection through a motif in the αβ T cell receptor. Science 281:835.
30. Corry, R. J., H. J. Winn, and P. S. Russell. 1973. Primarily vascularized allografts of hearts in mice: the role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation 16:343.
31. Kishimoto, K., V. M. Dong, S. Issazadeh, E. V. Fedoseyeva, A. M. Waaga, A. Yamada, M. Sho, G. Benichou, H. Auchincloss, Jr., M. J. Grusby, et al. 2000. The role of CD154-CD40 versus CD28-B7 costimulatory pathways in regulating allogeneic Th1 and Th2 responses in vivo. J. Clin. Invest. 106:63.
32. Akiba, H., H. Oshima, K. Takeda, M. Atsuta, H. Nakano, A. Nakajima, C. Nohara, H. Yagita, and K. Okumura. 1999. CD28-independent costimulation of T cells by OX40 ligand and CD70 on activated B cells. J. Immunol 162:7058.
33. Oshima, H., H. Nakano, C. Nohara, T. Kobata, A. Nakajima, N. A. Jenkins, D. J. Gilbert, N. G. Copeland, T. Muto, H. Yagita, and K. Okumura. 1998. Characterization of murine CD70 by molecular cloning and mAb. Int. Immunol. 10:517.
34. Yamada, A., K. Kishimoto, V. M. Dong, M. Sho, A. D. Salama, N. G. Anosova, G. Benichou, D. A. Mandelbrot, A. H. Sharpe, L. A. Turka, et al. 2001. CD28-independent costimulation of T cells in alloimmune responses. J. Immunol. 167:140.
35. + T cells. J. Immunol. 161:5236.
36. + T cell activation and tolerance in vivo. Am. J. Transplant. 3:1242.
37. + TCR transgenic mouse. Am. J. Transplant. 3:381.
38. Sha, W. C., C. A. Nelson, R. D. Newberry, D. M. Kranz, J. H. Russell, and D. Y. Loh. 1988. Positive and negative selection of an antigen receptor on T cells in transgenic mice. Nature 336:73.
39. Chalasani, G., Z. Dai, B. T. Konieczny, F. K. Baddoura, and F. G. Lakkis. 2002. Recall and propagation of allospecific memory T cells independent of secondary lymphoid organs. Proc. Natl. Acad. Sci. USA 99:6175.
40. Hancock, W. W., M. H. Sayegh, X. G. Zheng, R. Peach, P. S. Linsley, and L. A. Turka. 1996. Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection. Proc. Natl. Acad. Sci. USA 93:13967.
41. Judge, T. A., Z. Wu, X. G. Zheng, A. H. Sharpe, M. H. Sayegh, and L. A. Turka. 1999. The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival. J. Immunol. 162:1947.
42. Parker, D. C., D. L. Greiner, N. E. Phillips, M. C. Appel, A. W. Steele, F. H. Durie, R. J. Noelle, J. P. Mordes, and A. A. Rossini. 1995. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc. Natl. Acad. Sci. USA 92:9560.
43. Bishop, D. K., S. Chan, W. Li, R. D. Ensley, S. Xu, and E. J. Eichwald. 1993. CD4-positive helper T lymphocytes mediate mouse cardiac allograft rejection independent of donor alloantigen specific cytotoxic T lymphocytes. Transplantation 56:892.
44. Chen, Z., S. Cobbold, S. Metcalfe, and H. Waldmann. 1992. Tolerance in the mouse to major histocompatibility complex-mismatched heart allografts, and to rat heart xenografts, using monoclonal antibodies to CD4 and CD8. Eur. J. Immunol. 22:805.
45. Madsen, J. C., W. N. Peugh, K. J. Wood, and P. J. Morris. 1987. The effect of anti-L3T4 monoclonal antibody treatment on first-set rejection of murine cardiac allografts. Transplantation 44:849.
46. Lin, H., J. C. Rathmell, G. S. Gray, C. B. Thompson, J. M. Leiden, and M. L. Alegre. 1998. Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28. J. Exp. Med. 188:199.
47. -/- mice. Nat. Med. 7:557.
48. Sho, M., S. E. Sandner, N. Najafian, A. D. Salama, V. Dong, A. Vamada, K. Kishimoto, H. Harada, I. Schmitt, and M. H. Sayegh. 2002. New insights into the interactions between T-cell costimulatory blockade and conventional immunosuppressive drugs. Ann. Surg. 236:667.
49. Jacquot, S. 2000. CD27/CD70 interactions regulate T dependent B cell differentiation. Immunol. Res. 21:23.
50. Xiao, Y., J. Hendriks, P. Langerak, H. Jacobs, and J. Borst. 2004. CD27 is acquired by primed B cells at the centroblast stage and promotes germinal center formation. J. Immunol. 172:7432.
51. Takeda, K., H. Oshima, Y. Hayakawa, H. Akiba, M. Atsuta, T. Kobata, K. Kobayashi, M. Ito, H. Yagita, and K. Okumura. 2000. CD27-mediated activation of murine NK cells. J. Immunol. 164:1741.
52. McKay, D. B., H. Y. Irie, G. Hollander, J. L. Ferrara, T. B. Strom, Y. Li, and S. J. Burakoff. 1999. Antigen-induced unresponsiveness results in altered T cell signaling. J. Immunol. 133:6455.
53. + T cells and prolonged graft survival in a CTLA4-dependent manner. J. Immunol. 164:512.
54. Hendriks, J., L. A. Gravestein, K. Tesselaar, R. A. van Lier, T. N. Schumacher, and J. Borst. 2000. CD27 is required for generation and long-term maintenance of T cell immunity. Nat. Immunol. 1:433.
55. Lakkis, F. G., A. Arakelov, B. T. Konieczny, and Y. Inoue. 2000. Immunologic "ignorance" of vascularized organ transplants in the absence of secondary lymphoid tissue. Nat. Med. 6:686.
56. Suresh, M., J. K. Whitmire, L. E. Harrington, C. P. Larsen, T. C. Pearson, J. D. Altman, and R. Ahmed. 2001. Role of CD28-B7 interactions in generation and maintenance of CD8 T cell memory. J. Immunol. 167:5565.
57. + T cells and trigger acute rejection: an alternative mechanism of allorecognition. Nat. Med. 8:233.
58. Briscoe, D. M., and M. H. Sayegh. 2002. A rendezvous before rejection: where do T cells meet transplant antigens? Nat. Med. 8:220.
59. Gruss, H. J., N. Boiani, D. E. Williams, R. J. Armitage, C. A. Smith, and R. G. Goodwin. 1994. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 83:2045.
60. Smith, C. A., H. J. Gruss, T. Davis, D. Anderson, T. Farrah, E. Baker, G. R. Sutherland, C. I. Brannan, N. G. Copeland, N. A. Jenkins, et al. 1993. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 73:1349.
61. Weinberg, A. D. 1998. Antibodies to OX-40 (CD134) can identify and eliminate autoreactive T cells: implications for human autoimmune disease. Mol. Med. Today 4:76.
62. Gravestein, L. A., D. Amsen, M. Boes, C. R. Calvo, A. M. Kruisbeek, and J. Borst. 1998. The TNF receptor family member CD27 signals to Jun N-terminal kinase via Traf-2. Eur. J. Immunol. 28:2208.
63. Douin-Echinard, V., S. Bornes, P. Rochaix, A. F. Tilkin, J. M. Peron, J. Bonnet, G. Favre, and B. Couderc. 2000. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status. Cancer Gene Ther. 7:1543.
64. Braun-Falco, M., and M. Hallek. 2001. Recombinant adeno-associated virus (rAAV) vector-mediated cotransduction of CD70 and CD80 into human malignant melanoma cells results in an additive T-cell response. Arch. Dermatol. Res. 293:12.